Amplia Therapeutics Limited

ASX:ATX

Amplia Therapeutics Limited

ASX:ATX
TradeAdd trade order Follow Unfollow Set Price Alert
$0.165 (+3.1%)
Last close price
#90
Rank
5
Held by
6
Followers
TradeAdd trade order Follow Unfollow Set Price Alert
Reports My Report Forum Investors
Forum Topics ATX ATX 2 complete responses

Pinned straw:
lastever
Added 10 months ago

This is getting interesting. Out of 55 advanced pancreatic cancer patients enrolled in their phase 2a drug trial, Amplia have seen 15 partial responses and a week ago they reported 2 complete responses. The company says achieving 15 partial responses already indicated an improvement on standard-of-care (chemo) and they are only part way through the trial.

Actually, 10 of the initial 26 in the first cohort had already shown a partial response by January. If the second cohort responds similarly then the numbers will be unambiguous. Top line read out is due in Q3 2025.

What is a complete response? When no cancer can be detected in scans for 2 months. Extremely rare in advanced pancreatic cancer.

What is a partial response? When tumours appear to have shrunk.

What is the drug? An FAK inhibitor that breaks down the fibrous shield of cancers, being combined with standard-of-care chemo to make that more effective.

2 trials: There are two main types of chemo drug cocktails that Amplia's drug will be combined with in trial. The first is more common in Australia and is currently being trialled in Aust and Korea. The second is a more aggressive chemo favoured in the USA (soon to be trialled).
lastever
Added a month ago

A bit of good news on a pretty glum day. Amplia have discovered 4 additional complete responses for a total of 5 out of 55 patients in it's Accent pancreatic cancer trial. Or 6 if you include a pathological complete response. This rate of 7.8% complete response is apparently unheard of. (Complete response means the cancer has disappeared).

Median overall survival is now 11 months for an extra 2 months over standard-of-care chemo alone. 4 patients remain on trial. So the trial drug in combination with standard-of-care chemo provides a small but meaningful benefit overall, but has delivered the best news possible for a lucky few.

WIth a new Amplicity trial commencing in the USA and Australia in combination with a more aggressive chemo drug protocol used more commonly in the USA, Amplia is now going to be on everyone's radar.

8